IBC Life Sciences

Katja Arndt, Ph.D., Principal Investigator, Freiberg Institute for Advanced Studies

Claire Ashman, Senior Scientific Investigator, GlaxoSmithKline Medicines Research Centre

Michel Awwad, Ph.D., Director, Pfizer

Matthew Baker, Ph.D., Chief Scientific Officer, Antitope Ltd

Carlos Barbas III, Ph.D., Kellogg Professor of Molecular Biology and Chemist, The Scripps Research Institute

Dennis Benjamin, Ph.D., Senior Director, Chemistry & Antibody Technologies, Seattle Genetics, Inc.

Ramesh Bhatt, Ph.D., Vice President, Research, Sea Lane Biotechnologies

H. Kaspar Binz, Ph.D., Vice President of Technology & Co-Founder, Molecular Partners AG

Roland Brock, Ph.D., Chair, Biochemistry of Integrated Systems, Radboud University Nijmegen Medical Center

Kerry Chester, Ph.D., Professor of Molecular Medicine & Group Leader, UCL Cancer Institute

Ruth Cordoba-Rodriguez, Ph.D., Product Quality Reviewer, US FDA/CDER

Jonathan Davis, Ph.D., Principal Scientist, Protein Design, Adnexus, A Bristol-Myers Squibb R&D Co.

Annie De Groot, M.D., Founder, CEO and CSO, EpiVax, Inc.

Mark Dennis, Ph.D., Senior Scientist, Genentech. Inc.

Dimiter Dimitrov, Ph.D., Senior Investigator, NCI, NIH

Claire Dobson, Ph.D., Associate Director, Medimmune

Christina Furebring, Ph.D., Vice President, Alligator Bioscience

Scott Glaser, Ph.D., Director, Antibody Therapeutics, Biogen Idec, Inc.

Jochem Gokemeijer, Principal Scientist, Pharmacology, Adnexus, a Bristol Myers Squibb R&D Co.

Dragan Grabulovski, Ph.D., Chief Scientific Officer, Covagen AG

Fiona Harding, Ph.D., Associate Director, New Technologies, Facet Biotech

Stephen Harrison, Ph.D., Vice President, Research, KAI Pharmaceuticals Inc.

Christian Heinis, Ph.D., Tenure Track Assistant Professor, Ecole PolyTechnique Federale de Lausanne

Hanjo Hennemann, Ph.D.,, Executive Director and Head of R&D, Nexigen GmbH

Kristian Jensen, Ph.D., Chief Operating Officer, Pieris AG

Manuela Kaspar, Ph.D., Head of Protein Engineering, Philochem AG/Philogen S.p.A.

Joost Kolkman, Ph.D., Associate Director, Lead Optimization, Ablynx NV

Debbie Law, Ph.D., Chief Scientific Officer, Ablynx nv

Andrea Leone Bay, Ph.D., Vice President Pharmaceutical R&D, MannKind Corporation

Glen MacDonald, Ph.D., Chief Scientific Officer & VP, Operations, Viventia Biotechnologies, Inc.

Edwin Madison, Ph.D., Chief Scientific Officer, Catalyst Biosciences

James D. Marks, M.D.Ph.D., Professor, University of California San Francisco

Nick Marsh, Ph.D., Director, Pharmacology, Adnexus, a Bristol Myers Squibb R&D Co.

Bruce Morimoto, Ph.D., Vice President, Allon Therapeutics Inc.

Peter Morley, Ph.D., Investigator, GlaxoSmithKline

Karyn O'Neil, Ph.D., Chief Scientific Officer, Johnson & Johnson Ventures, Centocor R&D

William Pardridge, M.D., Chief Scientific Officer, ArmaGen Technologies, Inc.

Andreas Plueckthun, Ph.D., Professor of Biochemistry, University of Zurich

Amanda Proudfoot, Ph.D., Principal Scientist, Merck Serono Geneva Research Centre

Jack Ragheb, M.D., Ph.D., PI & Senior Regulatory Research Officer, CDER, FDA

Hilde Revets, Ph.D., Senior Director, Technology, Ablynx, NV

Tomi Sawyer, Ph.D., SVP and CSO, Aileron Therapeutics Inc

Volker Schellenberger, Ph.D., Vice President, Amunix, Inc.

Alessandro Sette, Ph.D., Head and Member, Center for Infectious Diseases, La Jolla Institute for Allergy and Immun

Sachdev Sidhu, Ph.D., Associate Professor, University of Toronto

Arne Skerra, Ph.D., CEO, XL-protein GmbH

An Song, Ph.D., Associate Director, Senior Scientist, Genentech

Paul Watt, Ph.D., CSO and VP Corporate Development, Phylogica Ltd.

David Wilson, Ph.D., VP of Biologics Acquisition and Validation, Cephalon, Inc.

Max Woisetschlager, Ph.D., Director of Target Biology, f-star Biotechnologische